Intergroupe Francophone de Cancerologie Thoracique

Quick facts

Marketed products

• Customized Treatment · Oncology
  Customized Treatment refers to personalized therapeutic approaches tailored to individual patient tumor characteristics and molecular profiles in thoracic oncology.

Phase 3 pipeline

• Chemotherapy with platine · Oncology
  Platinum-based chemotherapy agents form DNA crosslinks that prevent cancer cell replication and induce apoptosis.
• Gemcitabine alone · Oncology
  Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and cell death.
• Paclitaxel + Carboplatine · Oncology
  Paclitaxel and carboplatin work synergistically to kill cancer cells by stabilizing microtubules and causing DNA damage, respectively.

Phase 2 pipeline

• Paclitaxel, vinorelbine, cisplatin
• Pembrolizumab after randomization · Oncology
  PD-1 inhibitor
• Pembrolizumab before randomization

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Intergroupe Francophone de Cancerologie Thoracique portfolio CI brief
• Intergroupe Francophone de Cancerologie Thoracique pipeline updates RSS